Cargando…

Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma

Thyroid carcinoma (TC) accounts for ~2.1% of newly diagnosed cancer cases. Mutations in KRAS, HRAS, NRAS and BRAF are primary participants in the development and progression of various types of malignancy, including differentiated TC (DTC). Therefore, the present prospective cohort study aimed to sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashid, Faiza A., Bhat, Ghulam Hassan, Khan, Mosin S., Tabassum, Sobia, Bhat, Mohammad Hayat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739702/
https://www.ncbi.nlm.nih.gov/pubmed/35003743
http://dx.doi.org/10.3892/mco.2021.2478
_version_ 1784629158180028416
author Rashid, Faiza A.
Bhat, Ghulam Hassan
Khan, Mosin S.
Tabassum, Sobia
Bhat, Mohammad Hayat
author_facet Rashid, Faiza A.
Bhat, Ghulam Hassan
Khan, Mosin S.
Tabassum, Sobia
Bhat, Mohammad Hayat
author_sort Rashid, Faiza A.
collection PubMed
description Thyroid carcinoma (TC) accounts for ~2.1% of newly diagnosed cancer cases. Mutations in KRAS, HRAS, NRAS and BRAF are primary participants in the development and progression of various types of malignancy, including differentiated TC (DTC). Therefore, the present prospective cohort study aimed to screen patients with DTC for variations in RAS gene family and BRAF gene. Exon 1 and 2 of KRAS, HRAS, NRAS and exon 15 of BRAF gene were screened for hotspot mutations in 72 thyroid tumor and adjacent normal tissue samples using di-deoxy Sanger sequencing. HRAS T81C mutation was found in 21% (15 of 72) of DTC tissue samples, therefore this mutation was investigated in blood samples from patients with DTC and controls as a genetic polymorphism. In addition, HRAS T81C genotypes were determined in 180 patients with DTC and 220 healthy controls by performing restriction fragment length polymorphism. BRAF(V600E) mutation was confined to classical variant of papillary thyoid cancer (CPTC; 44.4%) and was significantly associated with multifocality and lymph node (LN) metastasis. No mutation was found in exons 1 and 2 of KRAS and NRAS and exon 2 of HRAS genes, however, mutation was detected in exon 1 of HRAS gene (codon 27) at nucleotide position 81 in 21% (15 of 72) of DTC tumor tissue samples. Furthermore, HRAS T81C single nucleotide polymorphism was significantly associated with the risk of DTC with variant genotypes more frequently detected in cases compared with controls (P≤0.05). Moreover, frequency of variant genotypes (TC+CC) was significantly higher among DTC cases with no history of smoking, males, greater age, multifocality and LN metatasis compared with healthy controls (P<0.05). BRAF(V600E) mutation was primarily present in CPTC and associated with an aggressive tumor phenotype but mutations in RAS gene family were not present in patients with DTC. HRAS T81C polymorphism may be involved in the etiopathogenesis of DTC in a Pakistani cohort. Furthermore, testing for the BRAF(V600E) mutation may be useful for selecting initial therapy and follow-up monitoring.
format Online
Article
Text
id pubmed-8739702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-87397022022-01-08 Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma Rashid, Faiza A. Bhat, Ghulam Hassan Khan, Mosin S. Tabassum, Sobia Bhat, Mohammad Hayat Mol Clin Oncol Articles Thyroid carcinoma (TC) accounts for ~2.1% of newly diagnosed cancer cases. Mutations in KRAS, HRAS, NRAS and BRAF are primary participants in the development and progression of various types of malignancy, including differentiated TC (DTC). Therefore, the present prospective cohort study aimed to screen patients with DTC for variations in RAS gene family and BRAF gene. Exon 1 and 2 of KRAS, HRAS, NRAS and exon 15 of BRAF gene were screened for hotspot mutations in 72 thyroid tumor and adjacent normal tissue samples using di-deoxy Sanger sequencing. HRAS T81C mutation was found in 21% (15 of 72) of DTC tissue samples, therefore this mutation was investigated in blood samples from patients with DTC and controls as a genetic polymorphism. In addition, HRAS T81C genotypes were determined in 180 patients with DTC and 220 healthy controls by performing restriction fragment length polymorphism. BRAF(V600E) mutation was confined to classical variant of papillary thyoid cancer (CPTC; 44.4%) and was significantly associated with multifocality and lymph node (LN) metastasis. No mutation was found in exons 1 and 2 of KRAS and NRAS and exon 2 of HRAS genes, however, mutation was detected in exon 1 of HRAS gene (codon 27) at nucleotide position 81 in 21% (15 of 72) of DTC tumor tissue samples. Furthermore, HRAS T81C single nucleotide polymorphism was significantly associated with the risk of DTC with variant genotypes more frequently detected in cases compared with controls (P≤0.05). Moreover, frequency of variant genotypes (TC+CC) was significantly higher among DTC cases with no history of smoking, males, greater age, multifocality and LN metatasis compared with healthy controls (P<0.05). BRAF(V600E) mutation was primarily present in CPTC and associated with an aggressive tumor phenotype but mutations in RAS gene family were not present in patients with DTC. HRAS T81C polymorphism may be involved in the etiopathogenesis of DTC in a Pakistani cohort. Furthermore, testing for the BRAF(V600E) mutation may be useful for selecting initial therapy and follow-up monitoring. D.A. Spandidos 2022-02 2021-12-23 /pmc/articles/PMC8739702/ /pubmed/35003743 http://dx.doi.org/10.3892/mco.2021.2478 Text en Copyright: © Rashid et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Rashid, Faiza A.
Bhat, Ghulam Hassan
Khan, Mosin S.
Tabassum, Sobia
Bhat, Mohammad Hayat
Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
title Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
title_full Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
title_fullStr Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
title_full_unstemmed Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
title_short Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
title_sort variations in map kinase gladiators and risk of differentiated thyroid carcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739702/
https://www.ncbi.nlm.nih.gov/pubmed/35003743
http://dx.doi.org/10.3892/mco.2021.2478
work_keys_str_mv AT rashidfaizaa variationsinmapkinasegladiatorsandriskofdifferentiatedthyroidcarcinoma
AT bhatghulamhassan variationsinmapkinasegladiatorsandriskofdifferentiatedthyroidcarcinoma
AT khanmosins variationsinmapkinasegladiatorsandriskofdifferentiatedthyroidcarcinoma
AT tabassumsobia variationsinmapkinasegladiatorsandriskofdifferentiatedthyroidcarcinoma
AT bhatmohammadhayat variationsinmapkinasegladiatorsandriskofdifferentiatedthyroidcarcinoma